Suggestions on the adjustment of therapeutic drugs for COPD in the national essential medicine list

ZHANG Licheng; GAO Ming; FENG Yufei; MA Yanliang; LENG Jiahua

doi:10.6039/j.issn.1001-0408.2023.16.03

您当前的位置：

首页 >

文章列表页 >

Suggestions on the adjustment of therapeutic drugs for COPD in the national essential medicine list

更新时间：2023-08-24

- Suggestions on the adjustment of therapeutic drugs for COPD in the national essential medicine list
- ZHONGGUO YAOFANG Vol. 34, Issue 16, Pages: 1931-1935(2023)
- 作者机构：
  
  1.北京大学肿瘤医院暨北京市肿瘤防治研究所医疗保险服务处/恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142
  2.北京大学人民医院药剂科，北京　100044
  3.北京大学人民医院呼吸内科，北京　100044
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.16.03
  CLC： R974;R95
- Published：30 August 2023，
  
  Received：22 March 2023，
  
  Revised：20 July 2023，
扫描看全文
张丽成,高明,封宇飞等.国家基本药物目录中COPD治疗药品的调整建议[J].中国药房,2023,34(16):1931-1935.

ZHANG Licheng,GAO Ming,FENG Yufei,et al.Suggestions on the adjustment of therapeutic drugs for COPD in the national essential medicine list[J].ZHONGGUO YAOFANG,2023,34(16):1931-1935.
张丽成,高明,封宇飞等.国家基本药物目录中COPD治疗药品的调整建议[J].中国药房,2023,34(16):1931-1935. DOI： 10.6039/j.issn.1001-0408.2023.16.03.

ZHANG Licheng,GAO Ming,FENG Yufei,et al.Suggestions on the adjustment of therapeutic drugs for COPD in the national essential medicine list[J].ZHONGGUO YAOFANG,2023,34(16):1931-1935. DOI： 10.6039/j.issn.1001-0408.2023.16.03.

摘要

目的

为慢性阻塞性肺疾病（COPD）的规范化治疗和国家基本药物目录中COPD治疗药品的调整提供参考。

方法

邀请相关临床专家、药学专家、医保专家共同梳理国内外COPD临床指南、国家基本药物目录、WHO基本药物标准清单、国家医保目录等收录的COPD治疗药品，并进行比较分析。

结果与结论

相较于国内临床治疗指南，国外临床指南多收录了1种COPD三联复合制剂，但后者收录的祛痰药及抗氧化剂种类较少；WHO基本药物标准清单收录的COPD治疗药品仅有12种，而我国基本药物目录收录了18种，后者包含更多的茶碱类、祛痰药及抗氧化剂。有15种COPD治疗药品被我国临床指南和国家医保目录收录，但未被国家基本药物目录收录，包括特布他林、盐酸左沙丁胺醇、沙美特罗、福莫特罗、茚达特罗、倍氯米松、糠酸莫米松、沙丁胺醇异丙托溴铵、格隆溴铵福莫特罗、乌美溴铵维兰特罗、茚达特罗格隆溴铵、倍氯米松福莫特罗、布地奈德/格隆溴铵/富马酸福莫特罗（布地格福）、糠酸氟替卡松/维兰特罗/乌美溴铵（氟替美维）、福多司坦，主要为长效β

受体激动剂和三联复合制剂。这些药品具有一定的循证医学证据，其疗效和经济性均有一定优势，且对医保基金预算的影响可控，建议后续基本药物目录更新调整时可考虑纳入。

Abstract

OBJECTIVE

To provide a reference for the standardized treatment of chronic obstructive pulmonary disease （COPD） and the adjustment of therapeutic drugs for COPD in the national essential medicine list.

METHODS

Relevant clinical experts， pharmaceutical experts and medical insurance experts were invited to sort out the COPD treatment drugs involved in the domestic and foreign COPD clinical guidelines， the national essential medicine list， the WHO standard list of essential medicine， the national medical insurance catalogue， and comparatively analyzed the COPD treatment drugs.

RESULTS &CONCLUSIONS

Compared with domestic clinical guidelines， foreign clinical guidelines included an additional COPD triple preparation， while involving fewer types of expectorants and antioxidants； there were only 12 kinds of COPD treatment drugs included in the WHO standard list of essential medicine， while there were 18 kinds in the national essential medicine list in China， and more theophylline drugs， expectorants and antioxidants were included. In addition， 15 kinds of COPD treatment drugs were found in both the national clinical guidelines and the national medical insurance catalogue， but not in the national essential medicine list， including terbutaline， levalbuterol hydrochloride， salmeterol， formoterol， indacaterol， beclometasone， mometasone furoate， salbutamol ipratropium， glycopyrronium formoterol， umeclidinium vilanterol， indacaterol glycopyrronium， beclometasone formoterol， budesonide/glycopyrrolate/formoterol fumarate， fluticasone furoate/vilanterol/umeclidinium， and fudosteine， which were mainly long-acting beta 2-agonists and COPD triple preparations. These drugs had certain evidence-based medicine evidence， their efficacy and economy had certain advantages， and their impact on the budget of the medical insurance fund was controllable. Therefore， it is suggested that the aforementioned drugs should be included in the essential medicines list in the subsequent update.

关键词

慢性阻塞性肺疾病基本药物目录医保目录长效β2受体激动剂三联复合制剂

Keywords

essential medicine listmedical insurance cataloguelong-acting beta 2-agonisttriple preparations

references

WANG C，XU J Y，YANG L，et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China（the China Pulmonary Health[CPH] Study）：a national cross-sectional study[J]. Lancet，2018，391（10131）：1706-1717.

李薇，杨汀，王辰. 中国慢性阻塞性肺疾病防治现状及进展[J]. 中国研究型医院，2020，7（5）：1-5.

国务院办公厅.国务院办公厅关于进一步做好短缺药品保供稳价工作的意见：国办发〔2019〕47号[EB/OL].（2019-10-11）[2023-02-02].https：//www.gov.cn/zhengce/content/2019-10/11/content_5438499.htmhttps://www.gov.cn/zhengce/content/2019-10/11/content_5438499.htm.

中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会，陈荣昌，等. 慢性阻塞性肺疾病诊治指南：2021年修订版[J]. 中华结核和呼吸杂志，2021，44（3）：170-205.

中华医学会，中华医学会杂志社，中华医学会全科医学分会，等. 慢性阻塞性肺疾病基层诊疗指南：2018年[J]. 中华全科医师杂志，2018，17（11）：856-870.

李正欢，张晓云，陈杨，等. 2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读：一：稳定期药物管理[J]. 中国全科医学，2021，24（8）：923-929.

陈亚红. 2023年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略更新要点[J/OL]. 中国医学前沿杂志（电子版），2023，15（2）：1-11（2023-02-01）[2023-03-02]. https：//kns.cnki.net/kcms2/article/abstract?v=3uoqIhG8C44YLTlOAiTRKibYlV5Vjs7ioT0BO4yQ4m_mOgeS2ml3UIhs4-nyD6AxSrfBpS5dgOnTPHAbpTzzXfxuA6stlfT34&uniplatform=NZKPT. DOI：10.12037/YXQY.2023.02-01https://kns.cnki.net/kcms2/article/abstract?v=3uoqIhG8C44YLTlOAiTRKibYlV5Vjs7ioT0BO4yQ4m_mOgeS2ml3UIhs4-nyD6AxSrfBpS5dgOnTPHAbpTzzXfxuA6stlfT34&uniplatform=NZKPT.DOI:10.12037/YXQY.2023.02-01.

中华医学会，中华医学会临床药学分会，中华医学会杂志社，等. 慢性阻塞性肺疾病基层合理用药指南[J]. 中华全科医师杂志，2020，19（8）：676-688.

慢性阻塞性肺疾病急性加重抗感染治疗中国专家共识编写组. 慢性阻塞性肺疾病急性加重抗感染治疗中国专家共识[J]. 国际呼吸杂志，2019，39（17）：1281-1296.

KEW K M，MAVERGAMES C，WALTERS J A E. Long-acting beta2-agonists for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev，2013（10）：CD010177.

张旻，周新. 超长效β2-受体激动剂茚达特罗在慢性阻塞性肺疾病中的临床疗效及安全性研究[J]. 中华结核和呼吸杂志，2013，36（8）：633-635.

HOHLFELD J M，VOGEL-CLAUSSEN J，BILLER H，et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD（CLAIM）：a double-blind，randomised，crossover，placebo-controlled，single-centre trial[J]. Lancet Respir Med，2018，6（5）：368-378.

NANNINI L J，POOLE P，MILAN S J，et al. Combined corticosteroid and long-acting beta（2）-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev，2013（8）：CD006826.

RABE K F，MARTINEZ F J，FERGUSON G T，et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD[J]. N Engl J Med，2020，383（1）：35-48.

慕欣. 建言基药目录调整：两年一调，设专项目录，落地配套[N]. 医药经济报，2022-12-15（1）.

国家卫生健康委药政司.关于就《国家基本药物目录管理办法（修订草案）》公开征求意见的公告[EB/OL].（2021-11-15）[2023-02-02].http：//www.nhc.gov.cn/wjw/yjzj/202111/068c31b85cb7486b9f77057b3e358aae.shtmlhttp://www.nhc.gov.cn/wjw/yjzj/202111/068c31b85cb7486b9f77057b3e358aae.shtml.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰